search
Back to results

Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
quality improvement toolkit
Sponsored by
Sunnybrook Health Sciences Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Atrial Fibrillation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Physicians are participants in the Electronic Medical Record Administrative-data Linked Database (EMRALD).
  • Patients are rostered to participating physicians, with a diagnosis in the chart of atrial fibrillation

Exclusion Criteria:

  • Physicians who do not consent to data sharing
  • Patients who change physicians during the course of the study

Sites / Locations

  • Institute for Clinical Evaluative Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Usual care

quality improvement toolkit

Arm Description

No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.

The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).

Outcomes

Primary Outcome Measures

Proportion of patients with AF receiving guideline-concordant stroke prevention therapy
Patients with risk factors for stroke (ie. CHADS2 >1 or age >65) who are prescribed anticoagulants and patients with no risk factors for stroke (ie. CHADS2 = 0 and age <65) who are not prescribed anticoagulants will be considered to be receiving guideline concordant therapy. (For patients with CHADS2 = 1 but aged < 65 the guideline recommendations are unclear, so these patients will not be considered in the primary analysis. For example, in patients with AF and hypertension at a younger age, anticoagulation or aspirin or no treatment would each be reasonable.)

Secondary Outcome Measures

proportion of patients taking warfarin in therapeutic range
patients must have INR measured 8 times during the year and therapeutic range assessed using Rosendaal method
proportion of patients taking a novel anticoagulant with appropriate dosing
Dabigatran, rivaroxaban and apixaban should be dose-adjusted in renal failure and avoided if estimated creatinine clearance is <30. Lower dose dabigatran is recommended for patients over 80.
proportion receiving aspirin
proportion receiving clopidogrel
proportion achieving target blood pressure
target defined as <130/80 for patients with diabetes, <150/80 for patients over 80, and <140/90 for all others

Full Information

First Posted
August 14, 2013
Last Updated
October 3, 2017
Sponsor
Sunnybrook Health Sciences Centre
Collaborators
Heart and Stroke Foundation of Ontario
search

1. Study Identification

Unique Protocol Identification Number
NCT01927445
Brief Title
Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care
Official Title
Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care: Protocol for a Pragmatic, Cluster-randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
April 2017 (Actual)
Study Completion Date
June 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sunnybrook Health Sciences Centre
Collaborators
Heart and Stroke Foundation of Ontario

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this project is to increase the proportion of patients with AF that receive adequate stroke prevention therapy. Over half of patients with AF who suffer strokes are permanently disabled. Yet there remains a large portion of patients who do not receive appropriate stroke prevention therapy. The investigators hypothesize that a toolkit of quality improvement strategies in primary care could increase the proportion of patients with atrial fibrillation appropriately treated with stroke prevention therapy. The investigators' goal is to ensure the toolkit of interventions can be easily incorporated into day-to-day practice in primary care and can be readily and broadly disseminated if successful.
Detailed Description
The prevalence of atrial fibrillation (AF) is growing as the population ages and 15% of all strokes are already attributed to AF. Unfortunately, half of patients with AF do not receive prescriptions for anticoagulation to prevent stroke due to a variety of system, provider, and patient-level barriers. The investigators will conduct a pragmatic, cluster-randomized controlled trial to test a 'toolkit' of quality improvement interventions in primary care. In keeping with the recommendations of the chronic care model to simultaneously facilitate proactive care by providers and activate patients, the toolkit includes provider- focused strategies (education, audit and feedback, electronic medical record-based tools including decision support and reminders) plus patient-directed strategies (educational letters and reminders). Thirty three primary care clinics will be randomized to the intervention or usual care. The trial will last 12 months and will be powered to show a difference of 10% in the primary outcome of proportion of patients receiving guideline-concordant care for stroke prevention. Analysis will be blind to allocation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
5000 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual care
Arm Type
No Intervention
Arm Description
No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
Arm Title
quality improvement toolkit
Arm Type
Experimental
Arm Description
The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
Intervention Type
Other
Intervention Name(s)
quality improvement toolkit
Intervention Description
educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
Primary Outcome Measure Information:
Title
Proportion of patients with AF receiving guideline-concordant stroke prevention therapy
Description
Patients with risk factors for stroke (ie. CHADS2 >1 or age >65) who are prescribed anticoagulants and patients with no risk factors for stroke (ie. CHADS2 = 0 and age <65) who are not prescribed anticoagulants will be considered to be receiving guideline concordant therapy. (For patients with CHADS2 = 1 but aged < 65 the guideline recommendations are unclear, so these patients will not be considered in the primary analysis. For example, in patients with AF and hypertension at a younger age, anticoagulation or aspirin or no treatment would each be reasonable.)
Time Frame
one year
Secondary Outcome Measure Information:
Title
proportion of patients taking warfarin in therapeutic range
Description
patients must have INR measured 8 times during the year and therapeutic range assessed using Rosendaal method
Time Frame
one year
Title
proportion of patients taking a novel anticoagulant with appropriate dosing
Description
Dabigatran, rivaroxaban and apixaban should be dose-adjusted in renal failure and avoided if estimated creatinine clearance is <30. Lower dose dabigatran is recommended for patients over 80.
Time Frame
one year
Title
proportion receiving aspirin
Time Frame
one year
Title
proportion receiving clopidogrel
Time Frame
one year
Title
proportion achieving target blood pressure
Description
target defined as <130/80 for patients with diabetes, <150/80 for patients over 80, and <140/90 for all others
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Physicians are participants in the Electronic Medical Record Administrative-data Linked Database (EMRALD). Patients are rostered to participating physicians, with a diagnosis in the chart of atrial fibrillation Exclusion Criteria: Physicians who do not consent to data sharing Patients who change physicians during the course of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen Tu, MD
Organizational Affiliation
ICES
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute for Clinical Evaluative Sciences
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27912776
Citation
Lee TM, Ivers NM, Bhatia S, Butt DA, Dorian P, Jaakkimainen L, Leblanc K, Legge D, Morra D, Valentinis A, Wing L, Young J, Tu K. Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. Implement Sci. 2016 Dec 3;11(1):159. doi: 10.1186/s13012-016-0523-2.
Results Reference
derived

Learn more about this trial

Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care

We'll reach out to this number within 24 hrs